Focal segmental glomerulosclerosis in a patient with multiple sclerosis treated with Teriflunomide and Ocrelizumab

• Published in: Journal of nephrology Vol. 36; no. 3; pp. 659 - 661
• Main Authors: Greve, Anne-Sofie, Prakash, Sivagini, Krag, Søren, Randers, Else
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01.04.2023
• Subjects: Adult; Albuminuria - chemically induced; Antibodies, Monoclonal, Humanized - adverse effects; Antibodies, Monoclonal, Humanized - therapeutic use; Case Report; Edema - chemically induced; Glomerulosclerosis, Focal Segmental - complications; Humans; Immunosuppressive Agents - adverse effects; Immunosuppressive Agents - therapeutic use; Male; Medicine; Medicine & Public Health; Multiple Sclerosis - drug therapy; Nephrology; Treatment Outcome; Urology

We describe the case of a 24-year-old male patient with multiple sclerosis (MS) who was treated with Teriflunomide for eight months. However, due to MS progression, treatment was switched to Ocrelizumab. After 15 months of therapy with Ocrelizumab the patient developed edema and nephrotic-range albu...